CalciMedica (CALC) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for CalciMedica (NASDAQ: CALC):

• 8/22/2026 – CalciMedica was upgraded by Wall Street Zen to “sell”.
• 8/20/2026 – CalciMedica is now covered by Guggenheim. They set a “buy” rating on the stock.
• 8/13/2026 – CalciMedica was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/13/2026 – CalciMedica had its “neutral” rating reaffirmed by UBS Group AG.
• 7/29/2026 – CalciMedica was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/29/2026 – CalciMedica had its “neutral” rating reaffirmed by HC Wainwright.
• 7/7/2026 – CalciMedica had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at CalciMedica

In related news, Director Fred A. Middleton acquired 248,972 shares of CalciMedica stock in a transaction dated Thursday, June 25th. The shares were acquired at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the completion of the transaction, the director directly owned 1,063,272 shares of the company’s stock, valued at $850,617.60. The trade was a 30.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 28.25% of the stock is currently owned by company insiders.

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.